Overview
Valued at
~$1.6 billion in 2023, the percutaneous transluminal angioplasty (PTA) balloons and
vena cava filters market is projected to reach
~$1.9 billion by 2028, increasing at a
CAGR of 3.7% over the 2023-2028 forecast period. This Market Snapshot is part of
LSI’s Market Intelligence platform, your
one-stop-shop for global medtech market sizing and analysis, procedure volume data, startup company- and
deal-tracking, curated insights, and more.
The PTA balloons and vena cava filters market encompasses several endovascular solutions for treating peripheral
artery disease (PAD), also called peripheral vascular disease (PVD). PTA balloons restore blood flow to vessels
occluded due to plaque buildup (atherosclerosis). They are often utilized in conjunction with
revascularization
techniques (e.g., atherectomy, intravascular lithotripsy) to restore blood flow in peripheral blood
vessels. Inferior vena cava filters, or IVC filters, are temporary or permanent devices that prevent thrombotic
material from traveling to the lungs.
Products included within the scope of this analysis include:
Peripheral angioplasty balloons
IVC filters
This Market Snapshot is intended to provide a high-level overview of the global market for PTA balloons and vena
cava filters, with key insights into:
Unit volumes from 2023 to 2028
Market forecasts from 2023 to 2028
Market insights
Competitive landscape analysis of major competitors
Insights into key market events for strategic and startups
PTA Balloons and Vena Cava Filters Market Snapshot Summary
| Snapshot Aspect |
Data and Details |
| Base Year for Estimate |
2023 |
| Forecast Period |
2023 - 2028 |
| Market Size in 2023 |
$1.6 billion |
| CAGR |
3.7% |
| Projected Market Size in 2028 |
$1.9 billion |
PTA Balloons and Vena Cava Filters Market Insights
The PTA balloons and vena cava filters market is primarily driven by the shift towards minimally invasive
solutions and advancements in the detection of PAD. As detection methods improve, the prevalence of PAD is
increasing, with some studies suggesting that PAD is rising at a faster rate than
coronary
artery disease. Many times, by the time PAD is detected, medications and lifestyle changes alone are
insufficient in managing blockages, necessitating an intervention.
Significant market events, such as clinical milestones, further shape market dynamics. For example, in November
of 2023, BD presented positive long-term results for its Lutonix™ drug-coated balloon (DCB), reinforcing the
safety of the device and positioning balloon angioplasty as the preferred endovascular intervention.
Fueled by demographic trends—particularly the rising population aged 65 and older—the PTA balloons market
continues to grow steadily. In contrast, the vena cava filters market is declining, with procedures dropping by
36% in the U.S. Medicare population from 2017 to 2022 due to ongoing safety concerns and recommendations for
limiting the use of filters by national organizations.
Competitive Landscape
The full Market Snapshot includes a robust analysis of the competitive landscape for the PTA balloons and vena
cava filters market. This includes estimated market revenue and market share for key players, such as Boston
Scientific, BD, and Cordis.
Select Market Events
|
Company
|
Date
|
Event Type
|
Event
|
|
|
10/2023
|
M&A
|
Cordis acquired drug-eluting balloon maker MedAlliance for $1.1 billion.
|
|
|
11/2023
|
Clinical
|
BD presented results from the SAFE-DCB Registry, showing the company’s Lutonix DCB was safe
and effective and provided durable long-term outcomes in over 1,000 patients.
|
Key Companies Covered
Abbott
B. Braun
BD
Biotronik
Boston Scientific
Brosmed
Comed
Cook Medical
Cordis
Degania Medical
Medtronic
Merit Medical
Nipro
OrbusNeich
Phillips
Summa Therapeutics
Terumo
TriReme Medical
